Advisory Alpha’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Advisory Alpha’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-625	Closed	-$2K	–	725
2020 Q3	$2K	Buy	+625	New	+$1.78K	﹤0.01%	637
2020 Q2	–	Sell	-625	Closed	-$2.81K	–	686
2020 Q1	$2.81K	Buy	+625	New	+$2.06K	﹤0.01%	564

Other funds holding BMY.RT

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BFS

Bard Financial Services Branford, Connecticut $911M AUM 19.14% 1-Year Est. Return

LGP

Leonard Green & Partners Los Angeles, California $2.77B AUM 3.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Advisory Alpha's BMY.RT Position: Q4 2020 in Review

Advisory Alpha sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 625 shares — an estimated $2K sold.

Advisory Alpha first reported a position in BMY.RT in Q1 2020 and held it in 2 quarters. The position peaked at $2.81K in Q1 2020. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

Advisory Alpha reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
Advisory Alpha sold 625 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $2K.
Advisory Alpha first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 2 quarters.
Advisory Alpha's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.81K in Q1 2020.
546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on Advisory Alpha's 13F filing for Q4 2020, filed 16 Feb 2021.